Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ReNeuron Group has treated first patient in Pilot Investigation of Stem Cells in Stroke (PISCES) Phase I trial evaluating ReN001 stem cell therapy for stroke in the UK.
Subscribe to our email newsletter
In the Phase I trial, ReNeuron’s ReN001stem cell therapy is being administered to stroke patients who have been left disabled by an ischaemic stroke.
The PISCES study (Pilot Investigation of Stem Cells in Stroke) is a regulated clinical trial of a neural stem cell therapy for disabled stroke patients.
According to the company, the first patient in the PISCES trial was treated at the Institute of Neurological Sciences, Southern General Hospital, Greater Glasgow and Clyde NHS Board and was safely discharged two days after the straightforward neuro-surgical procedure used to administer the ReN001 cells.
ReNeuron CEO Michael Hunt said that the initiation of the PISCES clinical trial is a hard-won milestone for ReNeuron and a significant milestone in the development of therapies to address the severely disabling effects of ischaemic stroke.
"We are delighted to be working with Professor Keith Muir and his team at one of Europe’s pre-eminent stroke treatment centres and, in so doing, helping to promote the uptake of clinical innovation in the NHS system," Hunt said.